(-0.06%) 5 305.07 points
(0.09%) 39 843 points
(-0.35%) 16 736 points
(-1.00%) $79.00
(-2.11%) $2.69
(-0.19%) $2 433.90
(-0.51%) $32.26
(0.03%) $1 064.00
(0.08%) $0.921
(-0.39%) $10.66
(-0.06%) $0.787
(-0.61%) $90.12
Live Chart Being Loaded With Signals
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases...
Stats | |
---|---|
本日の出来高 | 144 765 |
平均出来高 | 1.94M |
時価総額 | 208.13M |
EPS | $0 ( 2024-05-20 ) |
次の収益日 | ( $-0.0500 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.90 |
ATR14 | $0.00700 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Finn Jonathan | Buy | 25 000 | Common Stock |
2024-03-09 | Cigler Tessa | Buy | 20 834 | Stock Option (right to buy) |
2024-03-09 | Cigler Tessa | Buy | 0 | |
2023-11-15 | Weaver Gregory L | Sell | 50 000 | Common Stock |
2023-11-15 | Finn Jonathan | Buy | 62 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
70.91 |
Last 98 transactions |
Buy: 26 594 652 | Sell: 4 017 362 |
ボリューム 相関
Atossa Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
RETO | -0.916 |
RGF | -0.911 |
UONEK | -0.909 |
EEIQ | -0.909 |
HRZN | -0.909 |
TCPC | -0.905 |
CLEU | -0.901 |
TTEC | -0.898 |
QNRX | -0.897 |
GAN | -0.897 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Atossa Therapeutics Inc 相関 - 通貨/商品
Atossa Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-23 000.00 (0.00 %) |
EPS: | $-0.240 |
FY | 2023 |
収益: | $0 |
総利益: | $-23 000.00 (0.00 %) |
EPS: | $-0.240 |
FY | 2022 |
収益: | $0 |
総利益: | $-8 000.00 (0.00 %) |
EPS: | $-0.210 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.180 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Atossa Therapeutics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。